$DTIL
PRECISION BIOSCIENCES INC

2022 Q3 Form 10-Q Financial Statement

#000156459022028299 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $7.363M $3.820M $3.317M
YoY Change -69.37% -94.45% -79.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.33M $10.49M $10.69M
YoY Change 7.22% 5.5% 12.54%
% of Gross Profit
Research & Development $19.96M $22.94M $19.97M
YoY Change -16.96% -38.4% -21.96%
% of Gross Profit
Depreciation & Amortization $1.941M $1.929M $1.968M
YoY Change -14.27% -18.33% -9.72%
% of Gross Profit
Operating Expenses $30.29M $33.42M $19.97M
YoY Change -14.85% -29.15% -21.96%
Operating Profit -$22.93M -$29.60M -$27.34M
YoY Change 98.67% -236.84%
Interest Expense $405.0K $178.0K -$822.0K
YoY Change 636.36% 641.67% -1744.0%
% of Operating Profit
Other Income/Expense, Net -$1.016M -$1.434M -$833.0K
YoY Change -486.31% -6075.0%
Pretax Income -$23.95M -$31.04M -$28.17M
YoY Change 112.31% -243.31% 50.71%
Income Tax
% Of Pretax Income
Net Earnings -$23.95M -$31.04M -$28.17M
YoY Change 112.31% -243.31% 50.72%
Net Earnings / Revenue -325.22% -812.43% -849.2%
Basic Earnings Per Share -$0.22 -$0.46 -$0.46
Diluted Earnings Per Share -$0.22 -$0.46 -$461.5K
COMMON SHARES
Basic Shares Outstanding 110.8M 67.95M 61.03M
Diluted Shares Outstanding 110.8M 67.95M 61.03M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $212.1M $184.1M $116.2M
YoY Change 32.14% 5.86% -39.94%
Cash & Equivalents $212.1M $184.1M $116.2M
Short-Term Investments
Other Short-Term Assets $307.0K $418.0K $17.34M
YoY Change -98.61% -96.99% 170.98%
Inventory
Prepaid Expenses $12.29M $12.63M
Receivables $715.0K $50.51M $488.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $225.4M $247.7M $134.1M
YoY Change 23.12% 31.54% -38.82%
LONG-TERM ASSETS
Property, Plant & Equipment $21.79M $23.05M $27.77M
YoY Change -41.18% -40.28% -30.59%
Goodwill
YoY Change
Intangibles $1.969M $1.995M
YoY Change
Long-Term Investments $3.091M $1.351M $5.890M
YoY Change 280.67%
Other Assets $9.517M $9.332M $4.655M
YoY Change 125.74% 400.38% 158.61%
Total Long-Term Assets $46.37M $49.47M $47.30M
YoY Change 5.02% 18.32% 9.49%
TOTAL ASSETS
Total Short-Term Assets $225.4M $247.7M $134.1M
Total Long-Term Assets $46.37M $49.47M $47.30M
Total Assets $271.7M $297.2M $181.4M
YoY Change 19.6% 29.14% -30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.061M $797.0K $699.0K
YoY Change 118.31% 66.74% 74.75%
Accrued Expenses $10.45M $10.16M $7.101M
YoY Change 8.01% 6.84% -13.4%
Deferred Revenue $48.41M $41.51M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.15M $53.92M $29.11M
YoY Change 67.64% 48.75% -54.38%
LONG-TERM LIABILITIES
Long-Term Debt $22.17M $22.12M $2.482M
YoY Change
Other Long-Term Liabilities $217.0K $227.0K $80.10M
YoY Change -99.76% -53.39% 20334.69%
Total Long-Term Liabilities $217.0K $227.0K $82.59M
YoY Change -99.76% -53.39% 20967.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.15M $53.92M $29.11M
Total Long-Term Liabilities $217.0K $227.0K $82.59M
Total Liabilities $187.4M $194.1M $111.7M
YoY Change 48.98% 49.84% -45.11%
SHAREHOLDERS EQUITY
Retained Earnings -$399.8M -$375.9M
YoY Change
Common Stock $485.2M $479.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $952.0K $952.0K
YoY Change
Treasury Stock Shares
Shareholders Equity $84.38M $103.0M $69.66M
YoY Change
Total Liabilities & Shareholders Equity $271.7M $297.2M $181.4M
YoY Change 19.6% 29.14% -30.87%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$23.95M -$31.04M -$28.17M
YoY Change 112.31% -243.31% 50.72%
Depreciation, Depletion And Amortization $1.941M $1.929M $1.968M
YoY Change -14.27% -18.33% -9.72%
Cash From Operating Activities $29.19M -$24.22M -$28.87M
YoY Change -222.09% -22.7% -142.41%
INVESTING ACTIVITIES
Capital Expenditures -$1.090M -$779.0K -$818.0K
YoY Change -26.5% -53.77% -27.61%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.090M -$779.0K -$818.0K
YoY Change -26.5% -53.77% -27.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $46.70M $1.627M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -180.0K 92.92M 2.249M
YoY Change -101.51% 587.91% -93.87%
NET CHANGE
Cash From Operating Activities 29.19M -24.22M -28.87M
Cash From Investing Activities -1.090M -779.0K -818.0K
Cash From Financing Activities -180.0K 92.92M 2.249M
Net Change In Cash 27.92M 67.91M -28.87M
YoY Change -307.21% -448.0% -127.85%
FREE CASH FLOW
Cash From Operating Activities $29.19M -$24.22M -$28.87M
Capital Expenditures -$1.090M -$779.0K -$818.0K
Free Cash Flow $30.28M -$23.44M -$28.05M
YoY Change -235.03% -20.93% -140.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1995000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2048000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3595000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4180000
CY2022Q2 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3091000
CY2021Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
3091000
CY2022Q2 us-gaap Equity Method Investments
EquityMethodInvestments
1351000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
3751000
CY2022Q2 us-gaap Notes Receivable Net
NotesReceivableNet
7054000
CY2021Q4 us-gaap Notes Receivable Net
NotesReceivableNet
6879000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9332000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4641000
CY2022Q2 us-gaap Assets
Assets
297163000
CY2021Q4 us-gaap Assets
Assets
211498000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
797000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4050000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6765000
CY2022Q2 dtil Accrued Clinical And Research And Development Expenses
AccruedClinicalAndResearchAndDevelopmentExpenses
4186000
CY2021Q4 dtil Accrued Clinical And Research And Development Expenses
AccruedClinicalAndResearchAndDevelopmentExpenses
4028000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
41514000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21244000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1927000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1822000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1449000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
977000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
53923000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35980000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
104048000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
67015000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3823000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4813000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
22119000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
2478000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10000000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
227000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000
CY2022Q2 us-gaap Liabilities
Liabilities
194140000
CY2021Q4 us-gaap Liabilities
Liabilities
120330000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111605505
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110795033
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61712577
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60902105
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
479853000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
408795000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-375878000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316675000
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
952000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
103023000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
91168000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
297163000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
211498000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68805000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3820000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85154000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22936000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7137000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10485000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42908000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62828000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9938000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21176000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19436000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
33421000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
47173000
us-gaap Operating Expenses
OperatingExpenses
64084000
us-gaap Operating Expenses
OperatingExpenses
82264000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29601000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
21632000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56947000
us-gaap Operating Income Loss
OperatingIncomeLoss
2890000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1448000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2400000
CY2022Q2 us-gaap Interest Expense
InterestExpense
178000
CY2021Q2 us-gaap Interest Expense
InterestExpense
24000
us-gaap Interest Expense
InterestExpense
220000
us-gaap Interest Expense
InterestExpense
24000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
192000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
us-gaap Investment Income Interest
InvestmentIncomeInterest
364000
us-gaap Investment Income Interest
InvestmentIncomeInterest
101000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1434000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2256000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
77000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31035000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
21656000
us-gaap Net Income Loss
NetIncomeLoss
-59203000
us-gaap Net Income Loss
NetIncomeLoss
2967000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67954688
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57739622
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64512356
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57185402
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67954688
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59841638
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64512356
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59647367
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
44425000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1297000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
418000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3632000
CY2021Q1 dtil Stock Issued During Period Value Collaboration Partners
StockIssuedDuringPeriodValueCollaborationPartners
27739000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18689000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1353000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3896000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14826000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
21656000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
100553000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
91168000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
340000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4390000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1647000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28168000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
69659000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5138000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47670000
CY2022Q2 dtil Stock Issued During Period Value Collaboration Partners
StockIssuedDuringPeriodValueCollaborationPartners
11553000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31035000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
103023000
us-gaap Profit Loss
ProfitLoss
-59203000
us-gaap Profit Loss
ProfitLoss
2967000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3897000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4542000
us-gaap Share Based Compensation
ShareBasedCompensation
9528000
us-gaap Share Based Compensation
ShareBasedCompensation
7528000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-58000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-23000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
125000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
19000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
585000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
588000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2400000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
58822000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4802000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2695000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
50019000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9512000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
4779000
dtil Increase Decrease In Other Assets And Other Current Assets
IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets
200000
dtil Amortization Of Discount On Note Receivable
AmortizationOfDiscountOnNoteReceivable
175000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
192000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-2711000
dtil Increase Decrease In Accrued Other Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities
-905000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
43856000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6099000
dtil Increase Decrease In Lease Liability And Right To Use Asset Other Than Amortization Net
IncreaseDecreaseInLeaseLiabilityAndRightToUseAssetOtherThanAmortizationNet
885000
dtil Increase Decrease In Lease Liability And Right To Use Asset Other Than Amortization Net
IncreaseDecreaseInLeaseLiabilityAndRightToUseAssetOtherThanAmortizationNet
937000
dtil Increase Decrease In Contract Liability
IncreaseDecreaseInContractLiability
-10000000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-575000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
36733000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53096000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1597000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2815000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1597000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2815000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
378000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2647000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
282000
dtil Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
418000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49535000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9705000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
25000000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
35000000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19970000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
2470000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95165000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50227000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40472000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84145000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143663000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89798000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184135000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173943000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
505000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
308000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
190000
us-gaap Interest Paid Net
InterestPaidNet
103000
us-gaap Interest Paid Net
InterestPaidNet
5000
dtil Unsettled At The Market Issuances Of Common Stock Included In Other Current Assets
UnsettledAtTheMarketIssuancesOfCommonStockIncludedInOtherCurrentAssets
5121000
dtil Contract Liability Accrual Related To Servier Program Purchase Agreement Milestones
ContractLiabilityAccrualRelatedToServierProgramPurchaseAgreementMilestones
10000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-01-26
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46700000
CY2022Q2 dtil Underwriting Discounts And Commission
UnderwritingDiscountsAndCommission
3000000.0
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7100000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25154000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17434000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Registrant Name
EntityRegistrantName
PRECISION BIOSCIENCES INC
dei Entity Central Index Key
EntityCentralIndexKey
0001357874
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38841
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4206017
dei Entity Address Address Line1
EntityAddressAddressLine1
302 East Pettigrew St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A-100
dei Entity Address City Or Town
EntityAddressCityOrTown
Durham
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27701
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
314-5512
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000005 per share
dei Trading Symbol
TradingSymbol
DTIL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
110818008
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184135000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143663000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
50507000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
488000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12632000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
418000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
169000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
247692000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
161754000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23053000
CY2019Q2 dtil Common And Preferred Stocks Shares Authorized
CommonAndPreferredStocksSharesAuthorized
210000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000005
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5138000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3896000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9528000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7528000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7986
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7913
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0290
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0235
CY2022Q2 dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
1.25
dtil Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption
2.02
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9920314
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5608110
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.93
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
311235
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1302449
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.73
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13914740
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12800000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3071069
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4426623
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
40400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1138000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2323000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1594000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
529000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
545000
CY2022Q2 dtil Lessee Operating Lease Liability Payments Due In Five Years And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueInFiveYearsAndThereafter
372000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6501000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
751000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5750000
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0550
CY2022Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0650
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3033184
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3830130
CY2022Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-31035000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
21656000
us-gaap Net Income Loss
NetIncomeLoss
-59203000
us-gaap Net Income Loss
NetIncomeLoss
2967000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67954688
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57739622
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64512356
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57185402
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2102017
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2461966
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67954688
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59841638
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64512356
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59647367
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1

Files In Submission

Name View Source Status
dtil-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dtil-20220630_lab.xml Edgar Link unprocessable
dtil-20220630_pre.xml Edgar Link unprocessable
dtil-20220630_def.xml Edgar Link unprocessable
0001564590-22-028299-index-headers.html Edgar Link pending
0001564590-22-028299-index.html Edgar Link pending
0001564590-22-028299.txt Edgar Link pending
0001564590-22-028299-xbrl.zip Edgar Link pending
dtil-10q_20220630.htm Edgar Link pending
dtil-10q_20220630_htm.xml Edgar Link completed
dtil-20220630.xsd Edgar Link pending
dtil-ex104_251.htm Edgar Link pending
dtil-ex105_250.htm Edgar Link pending
dtil-ex311_6.htm Edgar Link pending
dtil-ex312_8.htm Edgar Link pending
dtil-ex321_9.htm Edgar Link pending
dtil-ex322_7.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending